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ABSTRACT 
The development of topical microbicide formulations for vaginal delivery to 
prevent HIV-2 sexual transmission is urgently needed. Second- and third-
generation polyanionic carbosilane dendrimers with silicon atom core and 16 
sulfonate (G2-S16), napthylsulfonate (G2-NS16) and sulphate (G3-Sh16) end-
groups have showed potent and broad-spectrum anti-HIV-1 activity. However, 
their antiviral activity against HIV-2 and mode of action has not been probed. 
Cytotoxicity, anti-HIV-2, anti-sperm and antimicrobial activities of dendrimers 
were determined. Analysis of combined effects of triple combinations with 
tenofovir and raltegravir were performed by using CalcuSyn software. We also 
assessed the mode of antiviral action on the inhibition of HIV-2 infection through 
a panel of different in vitro antiviral assays: attachment, internalization in 
PBMCs, inactivation and cell-based fusion. Vaginal irritation and histological 
analysis in female BALB/c mice were evaluated. 
Our results suggest that G2-S16, G2-NS16 and G3-Sh16 exert anti-HIV-2 
activity at an early stage of viral replication inactivating the virus, inhibiting cell-
to-cell HIV-2 transmission, blocking binding of gp120 to CD4, and HIV-2 entry. 
Triple combinations with tenofovir and raltegravir increased anti-HIV-2 activity, 
consistent with synergistic interactions (CIwt: 0.33-0.66). No vaginal irritation 
was detected in BALB/c mice after two consecutive applications for 2 days with 
3% G2-S16. 
This work clearly shows that G2-S16, G2-NS16 and G3-Sh16 have high 
potency against HIV-2 infection. The modes of action confirm their multifactorial 
and non-specific ability, suggesting that these dendrimers deserve further 
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studies as potential candidate microbicides to prevent vaginal/rectal HIV-1/HIV-
2 transmission in humans. 
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1. INTRODUCTION 
Human immunodeficiency virus (HIV) and other sexually transmitted infections 
are global threats to public health. Although HIV-1 strains are responsible for 
most of the global infections, HIV-2 strains are an important cause of disease in 
West African nations, Portugal, France, and in the United States.1, 2 Moreover, 
co-infection with both HIV-1 and HIV-2 occurs in some countries of West Africa 
where the viruses co-circulate.3, 4  
Sexual transmission is responsible for the majority of HIV-2 infections due to 
infected semen or cervico-vaginal secretions containing infected lymphocytes.5 
Ideally, a vaginal/rectal microbicide should have the following features: to be 
acceptable and affordable, offer maximal and immediate protection, remain in 
the vagina for a few hours to act against the sexual transmitted diseases 
(STDs) during and after sexual intercourse, not leak immediately after 
application, not accumulate to avoid toxicity effects, not affect the normal 
vaginal flora, and be compatible with male latex condom.6-8 
Dendrimers are a class of well-defined hyper-branched polymers with a 
nanoscale globular shape, well-defined functional groups at the periphery, 
hydrophobic/hydrophilic cavities in the interior and low polydispersity.9 
Dendrimers offer unique opportunities in the synthesis of agents with broad-
spectrum anti-HIV-1 activity and activity against Alzheimer’s disease, herpes 
simplex virus (HSV), bacteria, and cancer.10-14 A group of dendrimers with a 
carbosilane structure has demonstrated potential against HIV and other 
pathogens. These dendrimers are particularly suitable for this application due to 
the simplicity of their synthesis, which allows for large amounts of the polymer 
to be generated; the ability to obtain a polymer with a defined molecular weight 
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and number of terminal functions; chemical and biochemical stability; 
biologically inertness; and the low polarity of the C–Si bond, which imparts 
hydrophobicity to the carbosilane scaffold.15-17  
One of the most promising targets of the HIV cycle is the viral entry/fusion 
process, which is divided into three steps: (i) attachment of gp120 to CD4, (ii) 
binding to CCR5 and/or CXCR4, and (iii) fusion of the envelope with the cell 
membrane and releasing of the viral capsid into the cytoplasm of the host cell. 
18 Dendrimers containing functionalized groups at their periphery can bind to 
their target in a multivalent manner, providing a strategy for the development of 
potent viral entry inhibitors. Although the antiviral activity and the mode of action 
of carbosilane dendrimers have been studied against HIV-1, their antiviral 
activity against HIV-2 is currently unknown. Dendrimers may be important to 
fight HIV-2 infection as few of the currently available antiretroviral drugs work 
well against this virus and drug resistance is rapidly selected against the drugs 
that do work.19 
In order to identify dendrimers with potent anti-HIV-2 activity, we considered 
several polyanionic carbosilane dendrimers successfully tested for HIV-1 
applications with the objective of selecting those compounds with the best 
results obtained. In previous studies, we have shown that polyanionic 
carbosilane dendrimers G2-S16, G2-NS16, and G3-Sh16 (generations 
described as the number of repeating layers of silicon atoms forming the 
dendrimer, Fig. 1) had great anti-HIV-1 activity in vitro and in vivo.20-22 G2-S16 
and G2-NS16 consists of second-generation carbosilane dendrimers scaffold 
built from a silicon atom core, which is fully capped on the surface with 16 
sulfonate and napthylsulfonate groups, respectively. G3-Sh16 is a sulphate-
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terminated generation 3 carbosilane dendrimer, silicon-cored and also with 16 
anionic charges at the periphery. The anionic groups are in the form of sodium 
salts. Here, we have investigated the cytotoxicity, the anti-HIV-2 activity, and 
the anti-sperm and antimicrobial activities of G2-S16, G2-NS16, and G3-Sh16 
dendrimers. Moreover, we researched the anti-HIV-2 activity of combinations of 
these dendrimers with tenofovir and raltegravir. In order to discover more about 
the antiviral mechanism of action of these dendrimers, we used several in vitro 
experiments including: attachment and internalization of HIV-2 in PBMCs, HIV-2 
inactivation, and cell-based fusion assays. Finally, we show that vaginal 
application of 3% G2-S16 gel formulation does not cause vaginal irritation or 
lesions after histological analysis in female BALB/c mice.  
 
2. EXPERIMENTAL SECTION 
a. Dendrimers and reagents 
Polyanionic carbosilane dendrimers G2-S16 (C112H244N8Na16O48S16Si13; 
Molecular weight, Mw: 3,717.2 g/mol), G2-NS16 (C184H244N24Na16O56S16Si13; 
Mw: 4,934.0 g/mol) and G3-Sh16 (C256H508N48Na16O64S16Si29; Mw: 6,978.4 
g/mol) were synthesized as previously reported.15, 17 1mM stock solution of 
dendrimers and subsequent dilutions to obtain µM concentrations were 
prepared in distilled water. The reagents used as controls for inhibition of viral 
replication were the peptide HIV fusion inhibitor T-1249 (Trimeris, Inc., 
Morrisville, NC, USA), tenofovir (TFV; Gilead Sciences, Foster City, CA, USA), 
and raltegravir (RAL; Merck Sharp & Dohme Corp, Whitehouse Station, NJ, 
USA). Stock solutions were prepared in dimethyl sulfoxide (DMSO; Sigma-
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Aldrich, St. Louis, MO, USA), and serial dilutions to the intermediate 
concentrations were prepared using distilled water.  
b. Cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats 
obtained from healthy blood donors by a standard Ficoll-Hypaque density 
gradient (Rafer, Zaragoza, Spain) and cultured following the procedures of 
Spanish HIV-HGM BioBank.23, 24 When indicated, PBMCs were stimulated with 
2 µg/ml phytohemaglutinin (PHA; Remel, Santa Fe, NM, USA) and 20 U/ml IL-2 
(Bachem, Bubendorf, Switzerland) for at least 2 days before the experiments 
began. The protocol for maintaining the human epithelial TZM-bl and Hela cell 
lines (National Institute of Health AIDS Research and Reference Reagent 
Program, NIH-ARRRP) has been described.25-27 
c. Virus stocks and titration 
CCR5- and CXCR4-tropic primary HIV-2 clade A strains were isolated by co-
cultivation of PBMCs from infected subjects with PHA-activated PBMCs from 
healthy individuals.28 The 50% tissue culture infectious dose (TCID50) of viruses 
was determined in a single round viral infectivity assay using a luciferase 
reporter gene assay in TZM-bl cells as described previously.29  
The recombinant vaccinia virus vSC50 encodes the full-length env gene from 
HIV-2SBL/ISY, an X4-tropic infectious molecular clone, which was cloned into 
the vaccinia (WR) TK gene.30 Env gene expression is under control of the 
vaccinia virus P7.5 promoter.31 Virus stocks were tittered using the Reed & 
Muench method32 in Rat2 cells. 
d. Cytotoxicity assay 
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The safety and toxicity profile of G2-S16, G2-NS16 and G3-Sh16 in TZM-bl, 
Hela, and PBMCs cells was determined by MTT (3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazoliumbromide; Sigma) cytotoxicity assay according to 
manufacturer’s instructions.  
e. Antiviral assay 
TZM-bl cells were pretreated with serial dilutions of dendrimers for 1h at 37ºC. 
Cells were then infected with 200 TCID50 of virus-containing primary R5- or X4-
HIV-2 isolates for 2h at 37ºC. After 48h, the cells were washed and lysed, and 
the luciferase activity was measured by using a luciferase assay system kit 
(Promega, Madrid, Spain) according to the manufacturer’s instructions. From 
the dose-response curve, the 50% cytotoxic concentration (CC50) and the half-
maximal inhibitory concentration (IC50) of dendrimers were determined for each 
strain. The therapeutic index (TI) was determined by the following equation: 
TI=CC50/IC50.
33 
f. Inhibition of HIV-2 attachment and entry to PBMCs 
PHA-activated PBMCs were pretreated with dendrimers or controls for 1h. 
Then, primary HIV-2 isolates were added to PBMCs (the equivalent to 40 ng 
capsid protein/106 cells) and incubated for 2h at 4ºC. Unbound virus was 
removed by washing with phosphate-buffer saline (PBS; Lonza, Walkersville, 
MD, USA) three times, the cells were then lysed, and cell-bound viruses were 
quantified by the capsid p24 content in cell lysates. To measure internalization, 
the same conditions were used, except that PBMCs were incubated with virus 
for 2h at 37ºC, washed in acid wash (glycine 50 mM pH 3.2; Sigma) to strip 
surface-bound viral particles, and cell-internalizated viruses were quantified by 
the capsid p24 content in cell lysates. 
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g. HIV-2 inactivation  
Primary R5- or X4-HIV-2 isolates (the equivalent to 10 ng of the capsid protein) 
were incubated at 4ºC overnight into wells of a 96-well flat-bottom plate with 
poly-L-Lysine, to ensure the adherence of viral particles to the bottom of the 
well. Then, the wells were washed three times with PBS to remove unbound 
HIV-2 and treated with dendrimers or controls for 1h. PHA-activated PBMCs 
were then added. After 72h, cells were washed and lysed, and the HIV-2 p24 
Gag level in the cell lysates was quantified by using HIVp24gag ELISA kit 
(Innogenetics, Ghent, Belgium). Cell viability was measured by MTT assay.   
h. Cell-to-cell fusion inhibition 
Cell-to-cell fusion (CTC) inhibition was tested using a newly developed method 
with recombinant vaccinia virus expressing HIV-2 ISY env gene (vSC50). Hela 
cells were transfected using jetPRIME® reagent (Polyplus-transfection SA, 
Illkirch, France) with the Tat expressing plasmid pcDNA3.1+/Tat101-flag 
following manufacturer’s instructions and infected with the recombinant vaccinia 
virus. After 3h, Hela were collected and co-cultured with TZM-bl (CD4+, 
CCR5+, CXCR4+, indicator cells) at 1:1 cell density ratio in the absence or 
presence of increasing concentrations of dendrimers or controls. The 
percentage of membrane cell fusion was measured by luciferase activity 
induced by the Tat protein. The level of syncytium formation was determined by 
direct microscopic observation. 
i. Combination analysis between dendrimers and antiretrovirals 
TZM-bl cells were pretreated with different concentrations of 
dendrimer/antiretroviral (ARV) at a constant fixed ratio for 1h at 37ºC. The cells 
were then infected with the equivalent to 10 ng of the capsid protein of primary 
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R5-HIV-2 or X4-HIV-2 strains. 48h post-infection, the cells were washed and 
lysed and HIV-2 replication was quantified by luciferase activity. The IC50 and 
synergism were determined by using CalcuSyn software (Biosoft, Cambridge, 
UK). IC50 was determined by using the median-effect plot and the dose-
reduction index.34 Combination indices (CIs) were calculated based on the 
median-effect principle,35 where CI<0.9 indicates a synergistic effect, 
0.9<CI<1.1 indicates an additive effect, and CI>1.1 indicates an antagonism 
effect. 
j. Sperm processing and spermicidal activity 
Semen samples were collected by healthy volunteers by masturbation at the 
laboratory after 2-5 days of sexual abstinence and allowed to liquefy for 30-45 
min at room temperature.36 If completely liquefied, G2-S16 was selected for 
evaluating the sperm motility at 24h according to previously described method. 
37 Only specimens with at least a final motile sperm concentration of 5x106/mL 
were used. These parameters were evaluated by using the Sperm Class 
Analyzer software (Microptic S.L., Barcelona, Spain). 
k. Antimicrobial assays 
G2-S16 was evaluated for its antimicrobial activity against Candida 
albicans ATCC 10231, Enterococcus faecalis ATCC 29212, Escherichia 
coli ATCC 25922, Klebsiella pneumonia ATCC 00603, Lactobacillus 
plantarum ATCC 14917, Pseudomonas aeruginosa ATCC 28753 and 
Staphylococcus aureus ATCC 29213 microorganisms. The antimicrobial activity 
of G2-S16 was measured using a broth microdilution test and serial 1:2 dilutions 
according to the Clinical and Laboratory Standards Institute (CLSI; formerly 
NCCLS) guidelines.  
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l. BALB/c mice vaginal irritation test 
Six- to eight-week-old female BALB/c mice (Charles River, Barcelona, Spain) 
were housed in a specific-pathogen-free animal facility at Centro de Biología 
Molecular ‘Severo Ochoa’ for at least one week before the experiments were 
conducted. All mice were maintained and treated according to protocols 
approved by the Institutional Animal Care and Research Committee. BALB/c 
mice were injected subcutaneously with 2 mg of medroxyprogesterone acetate 
(DepoProvera, Pfizer, New York, NY, USA) five days before treatment. To 
assess and conduct an easy, low-cost, and a reliable statistical comparison of 
irritation studies with minimal damage, mice were randomized into 3 groups 
(n=3 in each group). Forty microliters of 2% hydroxyethylcellulose (HEC; Bohm 
laboratories, Madrid, Spain) gel containing 3% G2-S16 was carefully applied to 
the vaginal vault of mice using a stainless steel feeding needle for one day or 
two consecutive days. On day 7, mice were euthanized and vaginal tissues 
were excised and fixed in 4% formaldehyde solution (Panreac, Barcelona, 
Spain) for histology. 
m. Histological studies in BALB/c 
Formalin-fixed excised vaginal tissues were submitted to the Anatomic 
Pathology Laboratory (anaPath, Granada, Spain) for embedding, sectioning and 
evaluation of hematoxylin-and-eosin-stained tissue by an experienced patholo-
gist. Sections were mounted on slides and were subjected to a blind evaluation 
for epithelial erosion, leukocyte infiltration, thickening of the lamina propria 
(edema), and vascular congestion. The inflammation scores were assigned by a 
semiquantitative system.38, 39 
n. Statistical analysis 
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The data are presented as mean values and standard deviations (SD). The 
statistical significance between a treatment group and untreated control was 
calculated by unpaired t-test using GraphPad Prism v5.0 software (GraphPad, 
San Diego, CA, USA). 
 
3. RESULTS 
a. Cell biocompatibility 
The biocompatibility of G2-S16, G2-NS16 and G3-Sh16 was evaluated in TZM-
bl, Hela, and PBMCs. Cells were treated for 48h with increasing concentrations 
of dendrimers, which were considered toxic when survival rate were <80%. G2-
NS16 and G3-Sh16 were considered non-toxic at 10 µM in PBMCs; G2-S16 
was toxic at 50 µM. G2-NS16 and G2-S16 were non-toxic at 100 µM in TZM-bl 
and Hela cells, whereas G3-Sh16 was non-toxic up to 50 µM (Fig. 2). 
Therefore, the in vitro working concentration selected as non-toxic for all types 
of cells to facilitate a better comparison between compounds was of 10 µM. 
b. Anti-HIV-2 activity 
Although R5- and X4-HIV-1 viruses are present in body fluids (blood, semen, 
cervicovaginal and rectal secretions), R5 variants predominate in early stages 
during the process of sexual transmission, and persist throughout the course of 
HIV disease.40 Moreover, late stage R5 HIV-1 variants show more rapid 
replication and higher cytopathicity relative to early stage R5 variants.41 
Previous studies have demonstrated a similar behavior of the viral coreceptor 
specificity during the course of HIV-2 infection.42, 43 Therefore, we analyzed the 
antiviral activity and the IC50 of G2-S16, G2-NS16 and G3-Sh16 against both 
early- and late-stage R5- and X4-HIV-2 isolates in TZM-bl cells. 
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The CC50 were >100 µM for G2-S16 and G2-NS16 in TZM-bl cells. The CC50 for 
G3-Sh16 was 90 µM in TZM-bl cells (Table 1). The concentrations of G2-S16 at 
which R5- and X4-HIV-2 isolates were inhibited by 50% (IC50) varied between 
1.12 and 4.56 µM. The pre-treatment of TZM-bl cells with 10 µM G2-S16 
resulted in 73-94% inhibition of infection by primary R5- and X4-HIV-2 isolates 
(Fig. 3a). Pretreatment of TZM-bl cells with G2-NS16 showed a dose 
dependent inhibition of HIV-2 infection with IC50 values ranging from 0.73 to 
1.07 µM (Table 1). G2-NS16 at 10 µM was the dendrimer with the best 
inhibition values against the primary R5- and X4-HIV-2 strains (>93%; Fig. 3b). 
G3-Sh16 also showed dose dependent inhibition in HIV-2 infection with IC50 
values ranging from 0.85 to 2.97 µM (Table 1). Maximum percentage of 
inhibition varied between 82-94% with 10 µM G3-Sh16 (Fig. 3c). 
The TI of a compound is the ratio between the toxic and the therapeutic dose to 
measure its relative safety. Although TI values depend on many factors, it is 
generally considered that a drug has a good safety profile whether its TI >10.44 
The TI values of G2-S16 and G3-Sh16 were in a range of >21.9 to >89.3, and 
43.5 to 105.9, respectively (Table 1). G2-NS16 showed the highest TI with 
values that varied between >93.5 and >137. 
Summarizing, the three dendrimers were highly active against HIV-2 infection in 
TZM-bl cells, G2-NS16 being the most potent and broad of them. 
c. Virus-cell attachment and viral entry to the susceptible host cells 
Viral entry is a process that involves the binding of a virus to the surface of a 
cell, fusion to the cell membrane, and internalization of the viral genome into the 
target cells. We evaluated whether G2-S16, G2-NS16 and G3-Sh16 is involved 
in HIV-2 binding or in entry steps in PHA-activated PBMCs. Virus attachment 
Page 15 of 47 Nanoscale
was measured at 4ºC, a temperature at which membrane fusion and 
endocytosis processes are ineffective. Virus internalization was evaluated by 
incubating the virus-cell mixture at 37ºC, a temperature that allows membrane 
fusion and viral entry.  
Treatment with 10 µM of G2-S16, G2-NS16 and G3-Sh16 significantly 
decreased the capacity of the primary X4-HIV-2 isolate to bind to PBMCs by 
55%, 62%, and 52%, respectively (p<0.0001; Fig. 4a). This pattern was similar 
to that observed for the primary R5-HIV-2 particles (58-75% infection inhibition), 
but the reduction was not significant. As for the internalization of the viruses into 
PBMCs albeit a reduction was observed for all dendrimers it was only significant 
for G2-S16 with X4-HIV-2 isolates (45% decrease at 10 µM; p<0.0001; Fig. 4b). 
In summary, the three dendrimers bound to target cells and perturbed the ability 
of the viral envelope to interact with its cell surface receptors. G2-NS16 was the 
dendrimer that best blocked the virus-cell binding processes.  
d. HIV-2 inactivation  
The mechanism of inhibition of polyanionic carbosilane dendrimers against HIV-
2 could also be associated to a direct viral inactivation, without forgetting the 
ability of dendrimers to block the gp120/CD4 interaction. Therefore, we 
evaluated the ability of G2-S16, G2-NS16 and G3-Sh16 to directly inactivate 
primary HIV-2 isolates before contact with PHA-activated PBMCs. 
The pre-treatment of primary X4-HIV-2 with 10 µM of G2-S16, G2-NS16 or G3-
Sh16 significantly decreased the infectivity of X4-HIV-2 after 1h of exposure 
(82-91% reduction; p<0.0001). This pattern was similar to that observed for the 
primary R5-HIV-2 (68-81% reduction), but the decrease was not significant (Fig. 
5). The cell viability was always over 80%. 
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To summarize, the pre-treatment with the dendrimers for 1h decreased the 
infectivity of the HIV-2 particles in a tropism-dependent manner, suggesting that 
the dendrimers act strongly on the virion. The best results of HIV-2 inactivation 
were obtained with the G2-NS16 dendrimer. 
e. Inhibition of cell-to-cell fusion and syncytium formation 
A Tat and luciferase-based fusion assay and a syncytium counting assay were 
developed and used to assess whether the dendrimers block cell-associated 
virus entry. 
In the presence of a Hela/TZM-bl cell mixture, G2-S16, G2-NS16 and G3-Sh16 
efficiently blocked fusion between both cell lines in a dose-dependent manner 
(Fig. 6a). We also observed a significant decrease in the number of syncytia 
when the cells were pre-treated with the dendrimers, in particular for G2-NS16, 
which acts like the fusion inhibitor control T-1249 (Fig. 6a). Inhibition of HIV-2 
CTC fusion requires higher concentrations of each dendrimer than inhibition of 
HIV-2 cell-free infection. The IC50 of G2-S16 for CTC inhibition was 8.4-fold 
higher than IC50 for cell-free virus infection. The IC50 of G2-NS16 and G3-Sh16 
for CTC inhibition was 4.4-fold higher than IC50 for cell-free virus infection (Fig. 
6b). 
In summary, our results indicate that the three dendrimers inhibit cell-associated 
HIV-2 infection in a dose-dependent manner, in particular G2-NS16, albeit at a 
higher concentration relative to the inhibition of cell-free infection.  
f. Combination of dendrimers and antiretrovirals against HIV-2 infection  
The anti-HIV-2 activity of triple drug combinations was assessed in a single 
cycle assay in TZM-bl cells. For these studies the dendrimers were combined 
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with TFV, a nucleoside RT inhibitor, and RAL, an integrase inhibitor, at 1:1:1 
fixed ratio.  
In G2-S16/TFV/RAL, the IC50 for G2-S16 decreased against the primary R5- 
and X4-HIV-2 isolates (IC50: 3.0-60.0 nM) compared with dendrimer treatment 
alone. A similar result was also observed for the ARVs against the two primary 
HIV-2 infections (IC50: 60-310 nM for TFV; IC50: 60 nM for RAL) compared with 
single-drug treatment (Fig. 7a). CI was then calculated to determine whether 
synergistic, additive or antagonistic effects against all primary HIV-2 isolates 
occurred after this combination. CI calculations showed synergism at 75, 90, 
and 95% inhibition of R5-HIV-2 (CI: 0.38-0.53) and X4-HIV-2 infection (CI: 0.47-
0.61) (Table 2). 
For G2-NS16/TFV/RAL, the IC50 for G2-NS16 dropped against the primary R5- 
and X4-HIV-2 isolates (IC50: 50.0-60.0 nM) compared with the dendrimers used 
alone. Reductions were also observed in the IC50 for TFV (IC50: 250-610 nM) 
and RAL (IC50: 100-240 nM) against the primary R5-HIV-2 and X4-HIV-2 
infection compared to the drug treatment alone (Fig. 7b). The average CI 
displayed stronger synergy at the calculated EC90, and EC95 inhibitory 
concentrations against R5-HIV-2 infection (CI: 0.24-0.30). CI values indicated a 
good synergistic inhibitory profile at the three EC75, EC90, and EC95 
concentrations against X4-HIV-2 infection (CI: 0.46-0.65) (Table 2). 
With G3-Sh16/TFV/RAL, a reduction in G3-Sh16 concentration was observed 
(IC50: 10-110 nM) against the primary R5- and X4-HIV-2 infection. The IC50 for 
TFV dropped against R5- and X4-HIV-2 infection (IC50: 260-620 nM) compared 
with TFV alone; and for RAL decreased against R5- and X4-HIV-2 infection 
(IC50: 100-360 nM) compared with the drug used alone (Fig. 7c). CI 
Page 18 of 47Nanoscale
determination showed synergistic interactions at the calculated EC75, EC90, and 
EC95 inhibitory concentrations against R5-HIV-2 infection (CI: 0.31-0.42).This 
combination exhibited synergism at 90%, and 95% inhibition of X4-HIV-2 (CI: 
0.60-0.64) (Table 2). 
In summary, the strongest synergistic interactions and the highest inhibition of 
infection in TZM-bl cells were observed with G2-NS16/TFV/RAL, which is 
consistent with the most potent activity of G2-NS16 alone relative to the other 
dendrimers. 
g. In vitro spermicidal activity 
To identify whether the topical microbicide candidate G2-S16 is spermostatic or 
spermicidal, sperm was cultured in the presence or absence of dendrimer and 
the progressive motility of the sperm was analyzed. No significant changes in 
sperm progressive motility of G2-S16 (at 10 and 50 µM) at 24h post-treatment 
were obtained compared with untreated control (Fig. 8a). 
This result indicates that G2-S16 can be considered safe to be used as topical 
vaginal microbicide because it did not alter the sperm motility and did not affect 
other sperm functions. Moreover, this finding is consistent with the results 
obtained with G2-NS16 and G3-Sh16 in previous studies.22  
h. Antimicrobial activity 
The normal vaginal microbiota contains a wide variety of bacterial species that 
maintain an acidic pH by hydrogen peroxide and lactic acid production.45 
Alterations in this ecosystem can cause several vaginal infections, such as 
bacterial vaginosis and Candida vaginitis, which represent the majority of these 
infections among women.46 A successful microbicide product has to be stable 
and biocompatible in normal vaginal flora, preventing HIV-2 transmission in this 
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highly complex microenvironment. Therefore, toxicity of G2-S16 against a 
composite population of bacteria observed in normal vaginal microbiota was 
analyzed. No antimicrobial activity of G2-S16 (at 10 and 50 µM) at 24h post-
treatment against the list of microorganisms cited in M&M was observed (Fig. 
8b). 
Summarizing, our findings are consistent with the results obtained with G2-
NS16 and G3-Sh16 in previous studies.22 It suggests that G2-S16 is a good 
potential candidate for the first biological barrier encountered by the viruses 
because G2-S16 did not have negative effects in the normal vaginal flora. 
 i. In vivo assay of G2-S16 in BALB/c mice model 
To evaluate whether microbicide exposure of G2-S16 resulted in toxicity and 
inflammation of the vaginal mucosa, G2-S16 at 3% was applied intravaginally to 
BALB/c mice, and pathological examination of the vaginal tissues was 
performed at 7 days post-application. Histopathological examination indicated 
that the application of one dose or two doses of 3% of G2-S16 gel-treated 




Sexual transmission is the main route of HIV spread throughout the world.47 In 
the absence of a prophylactic anti-HIV vaccine, microbicides could offer to 
women a new strategy to prevent sexually transmitted HIV.48-50 To identify 
alternative medicines that provide significant advantage compared to existing 
therapies, different mechanisms to inhibit the viral lifecycle before the 
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integrations should be considered, such as the process of receptor-mediated 
viral entry.  
Dendrimers containing several types of functionalized groups at their periphery 
have shown effective anti-HIV activity as non-specific microbicides.18, 51, 52 
SPL7013 (the active product of VivaGel®), a fourth generation polylysine-based 
dendrimer with 32 napthylsulfonate groups at the periphery, is the only topical 
nanomicrobicide that has advanced to human clinical trials for HIV-1/HSV-2 
prophylaxis. However, VivaGel® provided low activity against R5-HIV-1 isolates 
and epithelial injury after 7-14 days of twice-daily administration has been 
associated with an increased risk for HIV infection.53 A new water-soluble 
dendrimers with carbosilane structure, which are characterized by the easy 
availability of reagents, short reaction times, high reproducibility and quantitative 
yields of reaction, have been synthesized.15-17 These polyanionic carbosilane 
dendrimers are stable compounds and their microbicide capacity against HIV-1 
has been previously reported.22, 54 However, the potential microbicide capacity 
against HIV-2 infection is still unknown. Here, the anti-HIV-2 activity of G2-S16, 
G2-NS16 and G3-Sh16 and the mechanism of action were determined. 
It has been reported that in heterosexual HIV transmission, R5-tropic HIV 
variants dominate in the early stages of HIV disease,55 although X4-tropic HIV 
variants are also present in body fluids.56 We compared the half cytotoxic 
concentration of G2-S16, G2-NS16 and G3-Sh16 when exposed to TZM-bl cells 
(CC50 > 90 µM) with the concentration of these dendrimers at which R5- and 
X4-HIV-2 infectivity was inhibited by 50% (IC50: 0.73-4.56 µM). Then, the 
therapeutic index was determined (TI: 21.9 - >137) and used as an indicator of 
overall efficacy and safety. Despite the fact that TI was high (>10), G2-S16, G2-
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NS16 and G3-Sh16 are compounds that should be studied more thoroughly and 
carefully before passing to clinical trials. 
In the virucidal and HIV-2 inactivation assays, we observed the capacity to 
diminish the residual infectivity of HIV-2 particles after 1h of incubation with the 
dendrimers. These results suggest that diverse mechanisms of HIV-2 
inactivation may be involved. The dendrimers can (i) disrupt the integrity of the 
HIV-2 membrane decreasing the stability of viral RNA,57 (ii) bind to V3 loop,20, 58 
or (iii) interact and modify by denaturing the two disulfide bonds locate on the 
HIV-2 gp120 protein (an area implicates in binding to the CD4 receptor).59 
However, additional research is needed to define the mechanism of inactivation 
occurs. The observations previously obtained by molecular dynamics 
simulations support this idea because the mechanism of action is associated 
with electrostatic interactions between HIV gp120 and different functional 
groups of dendrimers.20 However, the HIV-2 inactivation has not still been 
studied and further experiments by molecular modeling should be performed. 
The ability to prevent HIV-2 binding to PBMCs but not entry can be explained by 
the existence of other effective mechanisms of attachment besides the direct 
HIV-2 fusion with the CD4 cell surface (i.e., through galactosyl-ceramide, ICAM-
1, LFA-1 or heparan sulfate),60 which are beyond the mode of action of the 
dendrimers. Another possibility is that virus-cell fusion occurs with the 
endosomal membrane following the endocytic uptake of virus particles.61 
However, all alternatives of HIV-2 entry can probably coexist, which is the 
reason why G2-S16, G2-NS16 and G3-Sh16 inhibit binding but do not inhibit 
completely the internalization. Finally, the HIV-2 capsid protein can be altered 
by the dendrimers during the passage to the cell and this leads to problems in 
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its disaggregation, most likely the p24 antigen enters the cell but RT, integrase 
and viral RNA do not. Consequently, HIV-2 particles are not infectious. 
The ability of HIV to spread between cells determines its virulence, with direct 
HIV CTC up to thousand fold more potent and efficient than infection by cell-
free virus particles.62, 63 It is known that CTC protects viruses from humoral 
immune responses and antiviral treatments, allowing the persistence of residual 
replication, and the establishment and maintenance of viral reservoirs. Previous 
studies have demonstrated that HIV-1 CTC is susceptible to ARVs and 
neutralizing antibodies.64-67 Here, we have developed a simple and highly 
effective assay to assess the activity of dendrimers and other drugs in CTC 
promoted by the HIV-2 envelope. We show that dendrimers can efficiently 
prevent cell HIV-2 CTC albeit at a higher concentration relative to cell-free 
infection. These results confirm that cell-to cell fusion is more difficult to inhibit 
than cell-free HIV infection62 and, more importantly, indicate that dendrimers 
can prevent cell-associated HIV-2 infection 
ARVs display great potential in the prevention of sexual HIV transmission. 
However, ARVs-based microbicides could increase the risk of emergence of 
multidrug-resistant mutants, drug-drug interactions, systematic absorption and 
adverse side effects associated with high drug concentrations and lifelong 
therapy.29, 68, 69 Therefore, to prevent these problems the ideal HIV microbicide 
should combine different classes of antiretroviral drugs acting in different targets 
with compounds that act in a non-specific way.18 Here, we have shown that 
dendrimer/TFV/RAL combinations at a fixed 1:1:1 ratio have significant 
synergistic interactions against the primary R5- and X4-HIV-2 isolates. Similar 
results have been previously obtained for HIV-1 using a combination of these 
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dendrimers with TFV and/or maraviroc.25, 70-72 G2-NS16/TFV/RAL was the most 
potent combination regimen against HIV-2 isolates, which is consistent with the 
higher anti-HIV-2 potency of the G2-NS16 dendrimer when given alone relative 
to the other dendrimers. 
The safety profile of a microbicide candidate should preserve its activity against 
HIV infection and other STDs (i.e., HSV-2) and be carefully evaluated before 
moving the candidate into clinical trials. It is also important to note that an 
algorithm focused on prevention of HIV infection should address whether the 
lead topical microbicide candidates are spermicidal. There are some evidences 
of harm through genital lesions with the spermicide nonoxynol-9 when is 
vaginally administered for preventing HIV and other STDs.73 Previously we have 
shown that G2-NS16 and G3-Sh16 do not induce changes in sperm motility.22 
In this work, we studied the anti-sperm and antimicrobial activity of G2-S16. The 
sperm motility and the different bacteria present in normal vaginal flora showed 
very similar response patterns compared to untreated control, indicating that 
G2-S16 is not an antimicrobial and spermicidal compound. The results confirm 
that this class of dendrimers is not spermicidal 
Several polyanionic polymers as entry inhibitors (i.e., Ushercell, Carraguard or 
PRO2000) showed an increased risk of HIV-1 infection because of the 
disruption of the integrity of mucosal epithelial surface.74 In the present work, we 
studied the safety of 3% G2-S16 gel on topical mucosal site using BALB/c mice 
model. We showed that G2-S16 displayed a good safety profile and did not 
cause alterations to the vaginal epithelium. For the topical application, the 
dendrimer establishes a film or a physical barrier to prevent the dissemination of 
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infected cells from the local mucosa to the regional lymph nodes and acts 
against the infection once virus has crossed the epithelial barrier.75 
 
5. CONCLUSIONS 
To summarize, our studies reveal that G2-S16, G2-NS16 and G3-Sh16 are non-
specific compounds that inhibit HIV-2 infection acting at different and early 
steps in the HIV-2 lifecycle. These dendrimers act directly on the virus, block 
HIV-2 replication at steps prior to the integration of proviral DNA into the 
infected host cell genome (binding and fusion/entry into target cells), block HIV-
2 CTC and are effective at non-cytotoxic concentration easily reachable in the 
mice model. The use of a combined therapy blocking HIV-2 infection at early 
steps in the HIV-2 lifecycle is highly effective to stop the infection over existing 
therapeutic approaches, as they may avoid virus entry into new target cells and 
accelerate the decay of the latent reservoirs for HIV.  
The delivery vehicle for the formulation of the dendrimers is important for a 
good distribution throughout the vagina or rectum. Therefore, novel routes of 
administration to those already known (topical gels, intravaginal rings or locally 
applied solid films and tablets) should be explored to improve the activity, 
accept ability and adherence of these dendrimers for the prevention of HIV-2 
infection and other STDs that enhances HIV. It would be also interesting to test 
the anti-HIV-2 activity of the microbicide in presence of semen and to study the 
hypersensitivity, photosensitivity and condom integrity in the presence of the 
microbicide. Finally, further studies including humanized mice to complement in 
vitro and in vivo findings should be considered avoiding high economic losses 
and time before reaching human clinical trials.  
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Our data suggests that these dendrimers are promising candidates for future 
microbicide clinical trials in the field for prevention of HIV-2 infection. The role of 
these parameters in G2-S16/TFV/RAL, G2-NS16/TFV/RAL and G3-




The following reagent was obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: vSC50 from Dr. Sekhar Chrakabarti and Dr. 
Bernard Moss. Trimeris Inc (USA) provided T-1249.  
 
 
7. FIGURE AND TABLE LEGENDS 
Figure 1. Molecular representation of second- and third-generation 
dendrimers. (A) G2-S16 with 16 sulfonate end groups; (B) G2-NS16 with 16 
naphthylsulfonate end groups; (C) G3-Sh16 with 16 sulphate end groups. The 
generation of dendrimers is determined by considering that each generation 
corresponds to the number of repeating layers of silicon atoms forming the 
dendrimer. Abbreviations: Mw= Molecular weight 
 
Figure 2. Cytotoxicity associated to polyanionic carbosilane dendrimers 
G2-S16, G2-NS16 and G3-Sh16. (A) TZM-bl, (B) Hela and (C) PBMCs cells 
were loaded with increased amounts of dendrimers in a range between 0.01 
and 100 µM; or treated with 10 µM dextran (innocuous control) or 10% of 
DMSO (control of cell death). Histograms represent the percentage of viable 
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cells as the mean ± SD of at least three independent experiments performed in 
triplicate (vs. NT). Abbreviations: DMSO= Dimethylsulfoxide; NT= Non-treated 
(medium alone). 
 
Figure 3. Anti-HIV-2 activity and dose-response curve obtained for 
polyanionic carbosilane dendrimers G2-S16, G2-NS16 and G3-Sh16 in 
TZM-bl cells. TZM-bl cells were pretreated with increased concentrations of (A) 
G2-S16, (B) G2-NS16, and (C) G3-Sh16 for 1h before HIV-2 infection 
(concentrations ranged from 0.31 to 20 µM). Equal amounts of virus-containing 
(2,000 TCID50) primary early/late R5- or X4-HIV-2 isolates were used. 
Luciferase activity was analyzed to 48h post-infection vs. control non-treated 
cells. Data represent the mean ± SD of three independent experiments 
performed in triplicate. 
 
Figure 4. Effect of polyanionic carbosilane dendrimers G2-S16, G2-NS16 
and G3-Sh16 on HIV-1 attachment and entry into PBMCs. PHA-activated 
PBMCs were pretreated with dendrimers (10 µM) or control (5 µM T-1249) for 
1h before the infection with primary R5- or X4- HIV-2 isolates. After infection for 
2h (A) at 4°C (binding) or (B) at 37°C (internalization), the cells were washed 
extensively (with glycine-acid washing for internalization assay) and lysed with 
0.1% Triton X-100 buffer. Attachment and internalization levels were quantified 
by the measure of p24 in cell lysates by p24 ELISA. Results represent the mean 
± SD of three independent experiments performed in triplicate. ***: p<0.0001 vs. 
untreated control. Abbreviations: PBMCs= Peripheral blood mononuclear cells; 
PHA= Phytohaemagglutinin. 
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 Figure 5. HIV-2 virus inactivation by polyanionic carbosilane dendrimers 
G2-S16, G2-NS16 and G3-Sh16 prior to infection the PBMCs. Primary R5- 
and X4- HIV-2 isolates (grey and white bars, respectively) were stuck on poly-L-
lysine coated plates and were treated with dendrimers (10 µM) or control (5 µM 
T-1249) 1h before exposure to PHA-activated PBMCs. After 72h, PBMCs 
supernatants were collected and p24 levels were measured by p24 capture 
ELISA. Cell viability was measured by MTT assay (black solid and dashed 
lines). Data are represented as the mean ± SD of three independent 
experiments performed in triplicate. ***: p<0.0001 vs. untreated control. 
Abbreviations: CI= Control of infection; PBMCs= Peripheral blood mononuclear 
cells; PHA= Phytohaemagglutinin. 
 
Figure 6. Inhibition of Env/CD4-mediated membrane fusion. The plasmid 
Tat+ (pcDNA 3.1/Tat 101-flag) was transfected using the jetPRIME® transfection 
reagent into Hela-CD4- cells. The cells were then infected with the rVVenv virus 
(rVV/ISY). After 3h, TZM-bl (indicator cells) and Hela (effector cells) were co-
cultured and treated with dendrimers at a range of concentrations (2.5-50 µM) 
or T-1249 (1.25-10 µM) for 48h. (A) Percentage of fusion was measured by 
luciferase activity vs. cell-to-cell fusion without treatment (NT) and by direct 
microscopic observation by quantification of the syncytium formation. Data 
represent the mean ± SD of three independent experiments performed in 
triplicate. (B) The half-maximal inhibitory concentration (IC50) for cell-free and 
cell-to-cell viral fusion. 
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Figure 7. The half-maximal inhibitory concentration (IC50) of polyanionic 
carbosilane dendrimers G2-S16, G2-NS16 and G3-Sh16 and antiretrovirals 
(tenofovir or raltegravir) alone and in combination in TZM-bl cells. Mean 
50% effective concentrations (IC50, nM) for (A) G2-S16/TFV/RAL, (B) G2-
NS16/TFV/RAL, and (C) G3-Sh16/TFV/RAL at an equimolar ratio (1:1:1) after 
infection with primary R5- and X4-HIV-2 isolates in TZM-bl cells. The white bars 
indicate the mean IC50 calculated for the compounds when added alone, and 
the gray bars indicate the mean IC50 calculated for the compounds when used 
in combination. Data are shown as the mean ± SD from three independent 
experiments performed in duplicate. Abbreviations: TFV= Tenofovir; RAL= 
Raltegravir 
 
Figure 8. Sperm survival index and antimicrobial activity after 24h of 
treatment with G2-S16. (A) Sperm were cultured in seminal plasma, in the 
presence or absence of different concentrations of G2-S16 (10 and 50 µM). The 
sperm progressive motility was measured by using the Sperm Class Analyzer 
software. A calculated sperm motility index value <75% was used to indicate 
sperm toxicity. Data are represented as the mean ± SD of three different 
donors. (B) The determination of the minimum inhibitory concentration 
(antimicrobial susceptibility) of G2-S16 at 10 and 50 µM, defined as the lowest 
concentration of an antimicrobial that will inhibit the visible growth of a 
microorganism after overnight incubation at 35ºC, is calculated by a modified 
Kirby-Bauer disk diffusion technique. 
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Figure 9. Effects of 3% G2-S16 on the vaginal mucosa in BALB/c mice 
model. Mice were inoculated (A) once or (B) twice for two consecutive days 
(with an interval of 24h between sessions) intravaginally with 40 µl of 2% HEC 
containing G2-S16 at 3% (8 mM). The vaginal tract was harvested from the 
mice at 7 days post-application. Formalin-fixed, paraffin-embedded tissues 
sections were stained with hematoxylin-eosin for evidence of morphological 
damage or evidence of inflammation. HEC-treated mice were included as 
reference control (data no shown). Photographs are representative of all treated 
mice. Original magnification 100X. (C) Histopathological examination of vaginal 
tissues. Data were calculated as the mean ± SD of the scores estimated at the 
vaginas of three mice in each group. † Individual score: 0=absence, 1=minimal, 
2=mild, 3=moderate, 4=severe irritation. ‡ The cumulative score for epithelial 
disruption, submucosal leukocyte infiltration, edema and vascular congestion 
were correlated to human vaginal irritation potential as follows: vaginal irritation 
index ≤8: Acceptable; 9-10: Borderline; ≥11: Unacceptable. The scoring system 
was established according to Eckstein et. al35 and Zhong et. al.36 Abbreviations: 
HEC= Hydroxyethylcellulose gel. 
 
Table 1. In vitro cytotoxicity and anti-HIV-2 activity of polyanionic 
carbosilane dendrimers G2-S16, G2-NS16 and G3-Sh16 in TZM-bl cells. 
† CC50: The cytotoxic concentration of the dendrimers that caused the reduction of 
viable cells by 50%. Data represents the mean ± SD of three independent experiments 
performed in triplicate. 
‡ IC50: The concentration of the dendrimers that resulted in 50% inhibition in HIV-2 
infection. Data represents the mean ± SD of three independent experiments performed 
in triplicate 
¥ TI: Therapeutic index is CC50/IC50 
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Table 2. Combination indices of three-drug combinations against HIV-2 
infection in TZM-bl cells. Computer-simulated combination index at 50, 75, 90 
and 95% inhibition of primary R5- and X4-HIV-2 infection in vitro in TZM-bl cells. 
CIs are presented as the mean ± SD from the average of three experiments 
performed in triplicate.  
† CI > 1.1 indicates antagonism (-); 1.1 > CI > 0.9 indicates additive effect (ad) and CI < 
0.9 indicates a synergistic effect. 
‡ Synergy levels: 0.9 > CI > 0.85: + (sight synergism); 0.85 > CI > 0.7: ++ (moderate 
synergism); 0.7 > CI > 0.3: +++ (synergism); 0.3 > CI > 0.1: ++++ (strong synergism); 
CI < 0.1; +++++ (very strong synergism). 
¥ Because high degrees of effects are more important to the treatment than the low 
degrees of effects, the weighted average CI value was assigned as CIwt = [CI50 + 2CI75 
+ 3CI90 + 4CI95]/10, where CI50, CI75, CI90, and CI95 are the CI values at 50, 75, 90, and 
95% inhibition, respectively.31, 32  
Abbreviations: CI= Combination index; RAL= Raltegravir; TFV= Tenofovir. 
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Polyanionic carbosilane dendrimers inhibit HIV-2 binding and subsequent 
internalization, inactivate the virus, block HIV-2 cell-to-cell fusion, and enhance 
the antiviral activity in combination with tenofovir/raltegravir compared to the 
compounds alone. 
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 Dendrimer HIV-2 CC50 (µM) 
†





G2-S16 Early R5-HSM2.03 >100 4.56 >21.9 
 Late R5-HCC12.3  2.46 >40.7 
 Early X4-CT03  1.12 >89.3 
 Late X4-HCC10.3  3.72 >26.9 
G2-NS16 Early R5-HSM2.03 >100 0.73 >137.0 
 Late R5-HCC12.3  1.07 >93.5 
 Early X4-CT03  0.81 >123.5 
 Late X4-HCC10.3  0.88 >113.6 
G3-Sh16 Early R5-HSM2.03 90 1.56 57.7 
 Late R5-HCC12.3  2.07 43.5 
 Early X4-CT03  0.85 105.9 
 Late X4-HCC10.3  0.85 105.9 
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 Triple Combination 
(Combination ratios) 





  50% 75% 90% 95%  
G2-S16 + TFV + RAL (1:1:1) R5 




0.53 ± 0.01 
+++ 
0.43 ± 0.01 
+++ 
0.38 ± 0.02 
+++ 
0.45 ± 0.02 
+++ 
 X4 
0.73 ± 0.05 
++ 
0.61 ± 0.01 
+++ 
0.52 ± 0.03 
+++ 
0.47 ± 0.05 
+++ 
0.54 ± 0.03 
+++ 
G2-NS16 + TFV + RAL (1:1:1) R5 
0.63 ± 0.09 
+++ 
0.42 ± 0.02 
+++ 
0.30 ± 0.01 
++++ 
0.24 ± 0.03 
++++ 
0.33 ± 0.04 
+++ 
 X4 
0.84 ± 0.02 
++ 
0.65 ± 0.05 
+++ 
0.52 ± 0.08 
+++ 
0.46 ± 0.09 
+++ 
0.55 ± 0.06 
+++ 
G3-Sh16 + TFV + RAL (1:1:1) R5 
0.51 ± 0.05 
+++ 
0.42 ± 0.05 
+++ 
0.35 ± 0.02 
+++ 
0.31 ± 0.01 
+++ 
0.36 ± 0.02 
+++ 
 X4 
0.84 ± 0.03 
++ 
0.73 ± 0.02 
+++ 
0.64 ± 0.05 
+++ 
0.60 ± 0.06 
+++ 
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